PAR 4.55% 23.0¢ paradigm biopharmaceuticals limited..

Ann: Paradigm to Present at Evercore ISI HealthCONx Conference, page-174

  1. 6,525 Posts.
    lightbulb Created with Sketch. 1951
    ""As previously announced, PAR will make a separate announcement in terms of the FDA Type C feedback when they are in receipt of it. Once we receive the feedback we will be detailing our clinical programs in the upcoming R&D day."

    That response is as limp as a wet rotting lettuce leaf.

    So the company could neither confirm or deny phase 3 could take up to two years longer and cost more and whether those additional costs are within the existing funding capacity or if they need another capital raise. Never mind the loss of two years of IP that could have been exploited.

    "they can't keep updating the market every 5 minutes there is looking like some change" - No one is asking them to update the market every five minutes. That is the whole point. No one was expecting them to make a market sensitive appointment in an interview, with no accompanying ASX announcement... yet here we are... a half baked announcement with no detail. Questions are asked for clarification and we get stuff all.


    Stop throwing around the big potential as an excuse. Just because the risk-reward opportunity remains high, does not give the company a free license to continually stuff things up and not cop some fair criticism.

    Do you seriously think that what has occurred is good management? Things were so clear, even you were prompted to contact the company to ask for more information.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
23.0¢
Change
0.010(4.55%)
Mkt cap ! $80.45M
Open High Low Value Volume
22.8¢ 23.3¢ 22.5¢ $46.92K 203.9K

Buyers (Bids)

No. Vol. Price($)
1 337 23.0¢
 

Sellers (Offers)

Price($) Vol. No.
23.5¢ 138166 5
View Market Depth
Last trade - 16.10pm 16/08/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.